BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 24780597)

  • 1. Synthesis of 5-substituted-1H-pyrazolo[4,3-d]pyrimidin-7(6H)-one analogs and their biological evaluation as anticancer agents: mTOR inhibitors.
    Reddy GL; Guru SK; Srinivas M; Pathania AS; Mahajan P; Nargotra A; Bhushan S; Vishwakarma RA; Sawant SD
    Eur J Med Chem; 2014 Jun; 80():201-8. PubMed ID: 24780597
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis, biological evaluation and docking studies of novel 2-substituted-4-morpholino-7,8-dihydro-5H-thiopyrano[4,3-d]pyrimidine derivatives as dual PI3Kα/mTOR inhibitors.
    Lei F; Sun C; Xu S; Wang Q; OuYang Y; Chen C; Xia H; Wang L; Zheng P; Zhu W
    Eur J Med Chem; 2016 Jun; 116():27-35. PubMed ID: 27043268
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-activity relationship studies of pyrazolo[3,4-d]pyrimidine derivatives leading to the discovery of a novel multikinase inhibitor that potently inhibits FLT3 and VEGFR2 and evaluation of its activity against acute myeloid leukemia in vitro and in vivo.
    Yang LL; Li GB; Ma S; Zou C; Zhou S; Sun QZ; Cheng C; Chen X; Wang LJ; Feng S; Li LL; Yang SY
    J Med Chem; 2013 Feb; 56(4):1641-55. PubMed ID: 23362959
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis, and biological activity of pyridopyrimidine scaffolds as novel PI3K/mTOR dual inhibitors.
    Saurat T; Buron F; Rodrigues N; de Tauzia ML; Colliandre L; Bourg S; Bonnet P; Guillaumet G; Akssira M; Corlu A; Guillouzo C; Berthier P; Rio P; Jourdan ML; Bénédetti H; Routier S
    J Med Chem; 2014 Feb; 57(3):613-31. PubMed ID: 24345273
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel pyrazolo[3,4-d]pyrimidine with 4-(1H-benzimidazol-2-yl)-phenylamine as broad spectrum anticancer agents: Synthesis, cell based assay, topoisomerase inhibition, DNA intercalation and bovine serum albumin studies.
    Singla P; Luxami V; Singh R; Tandon V; Paul K
    Eur J Med Chem; 2017 Jan; 126():24-35. PubMed ID: 27744184
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis, anticancer and radioprotective activities of some new pyrazolo[3,4-d]pyrimidines containing amino acid moieties.
    Ghorab MM; Ragab FA; Noaman E; Heiba HI; Aboulmagd SA
    Arzneimittelforschung; 2009; 59(2):96-103. PubMed ID: 19338140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preparation of 3-substituted-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-4-amines as RET kinase inhibitors.
    Dinér P; Alao JP; Söderlund J; Sunnerhagen P; Grøtli M
    J Med Chem; 2012 May; 55(10):4872-6. PubMed ID: 22559926
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and antiproliferative activity in vitro of new 2-, 3- or 4-substituted pyrido[2',3':3,4]pyrazolo[1, 5-a]pyrimidines.
    Poreba K; Wietrzyk J; Opolski A
    Acta Pol Pharm; 2006; 63(3):189-94. PubMed ID: 20085223
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis, biological evaluation and docking studies of 4-amino substituted 1H-pyrazolo[3,4-d]pyrimidines.
    Schenone S; Brullo C; Bruno O; Bondavalli F; Mosti L; Maga G; Crespan E; Carraro F; Manetti F; Tintori C; Botta M
    Eur J Med Chem; 2008 Dec; 43(12):2665-76. PubMed ID: 18342402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A hit to lead discovery of novel N-methylated imidazolo-, pyrrolo-, and pyrazolo-pyrimidines as potent and selective mTOR inhibitors.
    Lee W; Ortwine DF; Bergeron P; Lau K; Lin L; Malek S; Nonomiya J; Pei Z; Robarge KD; Schmidt S; Sideris S; Lyssikatos JP
    Bioorg Med Chem Lett; 2013 Sep; 23(18):5097-104. PubMed ID: 23932790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis of pyrazolo[3,4-d]pyrimidin-4(5H)-ones tethered to 1,2,3-triazoles and their evaluation as potential anticancer agents.
    Allam M; Bhavani AKD; Mudiraj A; Ranjan N; Thippana M; Babu PP
    Eur J Med Chem; 2018 Aug; 156():43-52. PubMed ID: 30006173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis, anticancer activity and docking studies of novel 4-morpholino-7,8-dihydro-5H-thiopyrano[4,3-d]pyrimidine derivatives as mTOR inhibitors.
    Zhu W; Sun C; Xu S; Wu C; Wu J; Xu M; Zhao H; Chen L; Zeng W; Zheng P
    Bioorg Med Chem; 2014 Dec; 22(24):6746-54. PubMed ID: 25468038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis and docking studies of novel thienopyrimidine derivatives bearing chromone moiety as mTOR/PI3Kα inhibitors.
    Zhu W; Chen C; Sun C; Xu S; Wu C; Lei F; Xia H; Tu Q; Zheng P
    Eur J Med Chem; 2015 Mar; 93():64-73. PubMed ID: 25659752
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Facile synthesis and antiproliferative activity of 7H-benzo[7,8]chromeno[2,3-d]pyrimidin-8-amines.
    Akrami H; Safavi M; Mirjalili BF; Dehghani Ashkezari M; Dadfar F; Mohaghegh N; Emami S; Salehi F; Nadri H; Ardestani SK; Firoozpour L; Khoobi M; Foroumadi A
    Eur J Med Chem; 2017 Feb; 127():128-136. PubMed ID: 28039771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RETRACTED: Design, synthesis, structure-activity relationship and kinase inhibitory activity of substituted 3-methyl-1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-ones.
    Lamie PF
    Bioorg Med Chem Lett; 2016 Jul; 26(13):3093-3097. PubMed ID: 27189674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Some pyrazole and pyrazolo[3,4-d]pyrimidine derivatives: synthesis and anticancer evaluation.
    Shamroukh AH; Rashad AE; Abdel-Megeid RE; Ali HS; Ali MM
    Arch Pharm (Weinheim); 2014 Aug; 347(8):559-65. PubMed ID: 24801813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis and anticancer evaluation of novel pyrazole, pyrazolo[3,4-d]pyrimidine and their glycoside derivatives.
    Nassar IF; El Farargy AF; Abdelrazek FM; Ismail NSM
    Nucleosides Nucleotides Nucleic Acids; 2017 Apr; 36(4):275-291. PubMed ID: 28323527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis and SAR of new-di-substituted pyridopyrimidines as ATP-competitive dual PI3Kα/mTOR inhibitors.
    Al-Ashmawy AAK; Ragab FA; Elokely KM; Anwar MM; Perez-Leal O; Rico MC; Gordon J; Bichenkov E; Mateo G; Kassem EMM; Hegazy GH; Abou-Gharbia M; Childers W
    Bioorg Med Chem Lett; 2017 Jul; 27(14):3117-3122. PubMed ID: 28571824
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 4-(N-Phenyl-N'-substituted benzenesulfonyl)-6-(4-hydroxyphenyl)quinolines as inhibitors of mammalian target of rapamycin.
    Venkateswarlu V; Pathania AS; Aravinda Kumar KA; Mahajan P; Nargotra A; Vishwakarma RA; Malik FA; Sawant SD
    Bioorg Med Chem; 2015 Aug; 23(15):4237-4247. PubMed ID: 26162498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, synthesis and biological evaluation of novel 4-alkynyl-quinoline derivatives as PI3K/mTOR dual inhibitors.
    Lv X; Ying H; Ma X; Qiu N; Wu P; Yang B; Hu Y
    Eur J Med Chem; 2015 Jun; 99():36-50. PubMed ID: 26046312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.